BSX BOSTON SCIENTIFIC CORP — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$43.19

Period return

-48.10 (-52.69%)

Volume

9.9M

2026-07-21O $43.06 H $43.72 L $42.89 C $43.19MA5 $43.73MA20 $44.16MA60 $49.67MA120 $60.56

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 07. 29.Highin 8 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 29.MediumHOLD2 months ago
Wolfe Research: Peer Perform
US analyst rating / recommendation change.
2026. 05. 29.LowBUY2 months ago
Citigroup: Buy
US analyst rating / recommendation change.
2026. 05. 29.LowBUY2 months ago
Leerink Partners: Outperform
US analyst rating / recommendation change.
2026. 05. 28.LowBUY2 months ago
Barclays: Overweight
US analyst rating / recommendation change.
2026. 05. 28.MediumHOLD2 months ago
Wells Fargo: Equal-Weight
US analyst rating / recommendation change.
2026. 05. 19.LowBUY2 months ago
Baird: Outperform
US analyst rating / recommendation change.
2026. 05. 19.LowBUY2 months ago
B of A Securities: Buy
US analyst rating / recommendation change.
2026. 05. 19.LowBUY2 months ago
Needham: Buy
US analyst rating / recommendation change.
2026. 05. 18.LowBUY2 months ago
BTIG: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $80.16 · 32 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 07. 29.	After market close (AMC)	$0.83	—	—	$5.38B	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$0.45	—	—	$4.66B	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$0.87	—	—	$12.19B	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$0.55	—	—	$7.98B	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	9,411,231	$590.55M	0.50%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	2,471,344	$235.64M	0.37%	—	New position
3	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	2,434,563	$232.14M	0.38%	—	New position
4	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	3,687,315	$231.38M	0.42%	—	New position

BOSTON SCIENTIFIC CORP보스턴사이언티픽

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 29.	Wolfe Research	—	Downgrade	Outperform → Peer Perform	—	Wolfe Research: Outperform → Peer Perform
2026. 05. 29.	Citigroup	—	Maintain	Buy → Buy	—	Citigroup: Buy
2026. 05. 29.	Leerink Partners	—	Maintain	Outperform → Outperform	—	Leerink Partners: Outperform
2026. 05. 28.	Barclays	—	Maintain	Overweight → Overweight	—	Barclays: Overweight
2026. 05. 28.	Wells Fargo	—	Downgrade	Overweight → Equal-Weight	—	Wells Fargo: Overweight → Equal-Weight
2026. 05. 19.	Baird	—	Maintain	Outperform → Outperform	—	Baird: Outperform